Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An open randomised trial was conducted to compare ceftazidime (120 mg/kg/day) with "conventional therapy" (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day) in the treatment of severe melioidosis. A paired restricted sequential trial designed to detect a reduction in mortality from 80 to 40% in culture-positive patients surviving greater than 48 hours was stopped after 22 months. Of the 161 patients entered into the study, 65 had bacteriologically confirmed melioidosis and 54 of these were septicaemic. Ceftazidime treatment was associated with a 50% (95% CI 19-81%) lower overall mortality than conventional treatment (74% vs 37%; p = 0.009) and should now become the treatment of choice for severe melioidosis.


Journal article



Publication Date





697 - 701


Actuarial Analysis, Administration, Oral, Adolescent, Adult, Aged, Ceftazidime, Child, Chloramphenicol, Clinical Trials as Topic, Doxycycline, Drug Evaluation, Drug Resistance, Microbial, Drug Therapy, Combination, Female, Humans, Injections, Intravenous, Male, Melioidosis, Middle Aged, Prospective Studies, Random Allocation, Sepsis, Sulfamethoxazole, Time Factors, Trimethoprim